Novartis (NYSE:NVS) Shares Gap Down - What's Next?

Key Points

• Novartis shares plunged roughly 12.8%, opening at $139.94 versus the prior close of $159.99, after setbacks in two late-stage drug studies.
• The company reported that del-desiran failed a key efficacy measure in myotonic dystrophy, while pelacarsen did not reduce cardiovascular events despite lowering Lp(a), raising concerns about its pipeline and major investments.
• Novartis reaffirmed its sales guidance through 2030, and analysts see potential upside from remibrutinib; however, the stock carries a consensus “Hold” rating with an average price target of $141.20.

Novartis AG (NYSE:NVS - Get Free Report)'s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $159.99, but opened at $139.94. Novartis shares last traded at $139.4910, with a volume of 1,588,628 shares changing hands.

More Novartis News

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis reaffirmed its sales guidance through 2030 despite the latest clinical setback, providing some reassurance that near-term performance remains supported by its existing portfolio. Novartis announces trial setback on del-desiran drug
• Positive Sentiment: Analysts continue to identify potential upside from remibrutinib, which Bank of America estimates could generate approximately $3 billion in peak annual multiple-sclerosis sales if successfully approved and commercialized. Novartis has a potential $3 billion MS opportunity
• Neutral Sentiment: Broader risk-off trading, including sharply lower U.S. stock futures, contributed to selling across large pharmaceutical and biotechnology stocks, amplifying Novartis-specific weakness. Novartis and other stocks moving lower
• Neutral Sentiment: Industry concerns over potential U.S. tariffs on imported generic medicines could pressure drug manufacturers and prices, although the warning came from Sandoz and is not a direct Novartis announcement. Swiss pharma CEO warns of generic drug tariff threat
• Negative Sentiment: Novartis said its late-stage del-desiran study for myotonic dystrophy failed to meet a key efficacy measure. The therapy was acquired through the company’s roughly $12 billion purchase of Avidity Biosciences, raising questions about the value and execution of that pipeline investment. Novartis del-desiran trial disappointment
• Negative Sentiment: Pelacarsen failed to reduce cardiovascular events in a late-stage study despite lowering Lp(a) cholesterol. The result undermines prospects for a potentially multibillion-dollar cardiovascular treatment and increases pressure on Novartis to deliver successful pipeline launches. Cholesterol drug setback casts doubt over multibillion-dollar race

Wall Street Analysts Forecast Growth

NVS has been the topic of several recent analyst reports. Citigroup reaffirmed a "buy" rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings reissued a "buy (b)" rating on shares of Novartis in a research report on Friday, July 24th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $141.20.

Novartis Price Performance

The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. The stock's 50 day simple moving average is $155.79 and its two-hundred day simple moving average is $153.67. The stock has a market cap of $264.81 billion, a price-to-earnings ratio of 20.95, a P/E/G ratio of 3.12 and a beta of 0.45.

Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The firm had revenue of $14.95 billion for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. On average, analysts forecast that Novartis AG will post 8.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Archer Investment Corp boosted its holdings in Novartis by 93.0% during the first quarter. Archer Investment Corp now owns 166 shares of the company's stock valued at $25,000 after purchasing an additional 80 shares in the last quarter. Highland Investment Advisors LLC bought a new position in shares of Novartis during the 2nd quarter worth approximately $25,000. Evolution Wealth Management Inc. boosted its stake in Novartis by 552.0% in the 2nd quarter. Evolution Wealth Management Inc. now owns 163 shares of the company's stock valued at $26,000 after buying an additional 138 shares in the last quarter. Atlatl Advisers LLC bought a new stake in Novartis in the second quarter valued at $26,000. Finally, CrossGen Wealth LLC acquired a new position in Novartis during the fourth quarter worth $28,000. Institutional investors and hedge funds own 13.12% of the company's stock.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.